REGISTRATION NOW CLOSED - SOLD OUT!
This meeting is sponsored by:
PROGRAMME
| 09.00 - 09.55 | Arrival, registration and coffee |
| 09.55 - 10.00 | Welcome and introduction |
| Session 1 | |
| 10.00 - 10.45 | FragLites - An Efficient Approach to Druggability Assessment and Hit Generation Prof Mike Waring, Newcastle University |
| 10.45 - 11.30 | Accelerating PROTAC drug discovery programs through application of a high-throughput chemistry, direct-to-biology platform John Harling, GSK |
| 11.30 - 12.15 | Discovery and validation of in vitro and in vivo probes for human DNA Polymerase theta (Polθ) Rob Heald, Artios Pharma |
| 12.15 - 13.15 | Lunch break |
| Session 2 | |
| 13.15 - 14.00 | Medicinal Chemistry optimization into clinical compound profiles and how the strategies are changing Malin Lemurell, AstraZeneca |
| 14.00 - 14.45 | Role and rise of data science within drug discovery Ben Sidders, AstraZeneca |
| 14.45 - 15.05 | Tea break |
| Session 3 | |
| 15.05 - 15.50 | ML/AI: Opportunities, Impact and Future Directions in Drug Design Richard Sherhod, BenevolentAI |
| 15.50 - 16.50 | Keynote talk: Nanobodies as enabling technology for structural biology and promising therapeutics Prof Jim Naismith, Rosalind Franklin Institute, Harwell Campus |
| 16.50 | Closing comments and end of meeting |